ArticleAIMS genetics2019

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety.

Sharvesh Raj SeeruttunPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.